The RNA delivery dilemma-lipid versus polymer nanoparticle platforms

Drug Deliv Transl Res. 2026 Jan 30. doi: 10.1007/s13346-026-02044-6. Online ahead of print.ABSTRACTSince the first market authorization of RNA therapies, just eight years ago, the field has witnessed an extraordinary expansion, ranging from hepatic delivery for rare genetic diseases to global-scale

C ClĂ¡udia Martins